4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
TScan Therapeutics, Inc. (TCRX) operates in the Biotechnology industry and is headquartered in Waltham, United States with about 138 employees. Its market capitalization is roughly $69 million. In the fiscal year ended 2025-12-31, TCRX reported $10M in revenue and ($130M) in net income.
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States.
Interactive charts & full statements → Open the TCRX valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $10M | $3M | $21M | $14M | — |
| Operating Income (EBIT) | ($136M) | ($135M) | ($94M) | ($67M) | — |
| Net Income | ($130M) | ($128M) | ($89M) | ($66M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $1M | $3M | $2M | $3M | $2M | — |
| Operating Income (EBIT) | ($29M) | ($24M) | ($37M) | ($39M) | ($36M) | — |
| Net Income | ($29M) | ($23M) | ($36M) | ($37M) | ($34M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dividends Paid | $0M | $0M | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Dividends Paid | $0M | $0M | $0M | $0M | $0M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $229M | $371M | $272M | $199M | — |
| Total Liabilities | $106M | $130M | $121M | $100M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive TCRX viewer.
About TickerBase · Data methodology & sources